Business Description
Novelix Pharmaceuticals Ltd
SIC : 2834
ISIN : INE314I01036
Total Employee Number:
8Compare
Compare
Traded in other countries / regions
536565.India IPO Date
2009-03-25Description
Novelix Pharmaceuticals Ltd is an Indian company engaged in the trading of pharmaceutical and related products, and it also trades in shares and securities. Its pharmaceutical trading operations account for the majority of its revenue, supplying medicines and allied products to distributors, pharmacies, and other buyers in the domestic Indian market. The securities trading segment contributes a smaller share of overall revenue and involves dealing in listed equities and other financial instruments. The company operates primarily within India and generates income through the sale of traded pharmaceutical goods and through gains and income from its securities trading activities. Its business model is trading-oriented rather than manufacturing-based, meaning it purchases products from suppliers and resells them to customers without significant in-house production.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.69 | |||||
Equity-to-Asset | 0.5 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | 0.93 | |||||
Interest Coverage | 38.4 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 5.2 | |||||
Beneish M-Score | 3.78 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 230.8 | |||||
3-Year FCF Growth Rate | -59.9 | |||||
3-Year Book Growth Rate | 35.4 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 42.91 | |||||
9-Day RSI | 47.54 | |||||
14-Day RSI | 50.34 | |||||
3-1 Month Momentum % | -4.57 | |||||
6-1 Month Momentum % | 40.15 | |||||
12-1 Month Momentum % | 95.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.94 | |||||
Quick Ratio | 1.62 | |||||
Cash Ratio | 0.06 | |||||
Days Inventory | 15.95 | |||||
Days Sales Outstanding | 110.86 | |||||
Days Payable | 82.63 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 4.81 | |||||
Operating Margin % | 3.02 | |||||
Net Margin % | 2.47 | |||||
EBITDA Margin % | 3.15 | |||||
FCF Margin % | -17.46 | |||||
OCF Margin % | -15.24 | |||||
ROE % | 12.14 | |||||
ROA % | 5.69 | |||||
ROIC % | 13.42 | |||||
3-Year ROIIC % | 7.11 | |||||
ROC (Joel Greenblatt) % | 23.89 | |||||
ROCE % | 14.95 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 44.46 | |||||
PE Ratio without NRI | 44.46 | |||||
PS Ratio | 0.97 | |||||
PB Ratio | 3.55 | |||||
Price-to-Tangible-Book | 3.67 | |||||
EV-to-EBIT | 47.6 | |||||
EV-to-EBITDA | 45.95 | |||||
EV-to-Revenue | 1.44 | |||||
EV-to-FCF | -8.2 | |||||
Price-to-Median-PS-Value | 1.21 | |||||
Price-to-Graham-Number | 3.05 | |||||
| Price-to-Net-Current-Asset-Value | 3.8 | |||||
Earnings Yield (Greenblatt) % | 2.1 | |||||
FCF Yield % | -11.51 | |||||
Forward Rate of Return (Yacktman) % | -32.52 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Novelix Pharmaceuticals Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 1,468.689 | ||
| EPS (TTM) (₹) | 1.765 | ||
| Beta | 1.0078 | ||
| 3-Year Sharpe Ratio | 1.78 | ||
| 3-Year Sortino Ratio | 7.01 | ||
| Volatility % | 53.03 | ||
| 14-Day RSI | 50.34 | ||
| 14-Day ATR (₹) | 4.746966 | ||
| 20-Day SMA (₹) | 79.0275 | ||
| 12-1 Month Momentum % | 95.23 | ||
| 52-Week Range (₹) | 38 - 92 | ||
| Shares Outstanding (Mil) | 28.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Novelix Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Novelix Pharmaceuticals Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| 10:1 Stock Split | 2009-10-15 | 51.05 (+0.00%) |
Show
Entries
Novelix Pharmaceuticals Ltd Frequently Asked Questions
What is Novelix Pharmaceuticals Ltd(BOM:536565)'s stock price today?
The current price of BOM:536565 is ₹77.50. The 52 week high of BOM:536565 is ₹92.00 and 52 week low is ₹38.00.
When is next earnings date of Novelix Pharmaceuticals Ltd(BOM:536565)?
The next earnings date of Novelix Pharmaceuticals Ltd(BOM:536565) is .
Does Novelix Pharmaceuticals Ltd(BOM:536565) pay dividends? If so, how much?
Novelix Pharmaceuticals Ltd(BOM:536565) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers